Sandbox 645: Difference between revisions
| Line 12: | Line 12: | ||
=='''Applications & Research'''== | =='''Applications & Research'''== | ||
When a HIV virus infects an organism it tends to multiply within the body’s cells. The virus is then released to infect other cells. In this manner, the infection of HIV infects the newly made cells of the body. While the viruses are produced, proteins and enzymes used to manufacture the DNA in addition to other components of the virus are made. In this case, protease is that enzyme that is needed to bring the structural and enzymes of the virus together. Protease drugs are what could inhibit this virus. | When a HIV virus infects an organism it tends to multiply within the body’s cells. The virus is then released to infect other cells. In this manner, the infection of HIV infects the newly made cells of the body. While the viruses are produced, proteins and enzymes used to manufacture the DNA in addition to other components of the virus are made. In this case, protease is that enzyme that is needed to bring the structural and enzymes of the virus together. Protease drugs are what could inhibit this virus. | ||
HIV Drugs: | |||
*HIV Drugs: | |||
1) Saquinavir (Invirase) is known to be one of the first FDA approved protease inhibitor for HIV treatment. This usually occurs by HIV protease binding an active site tunnel tightly, which will prevent polyproteins from also binding. HIV’s chemical structure has the ability to mimic the tetrahedral intermediate of the hydrolytic reaction to interact strong with the catalytic Asp residues. Knowing that, Saquinavir is an uncleavable ligand by studying its similar conformational changes in binding saquinavir or a polypeptide. ((http://www.rxlist.com/invirase-drug.htm)))) [[Image:Saquin1.gif|thumb|Saquinavir mesylate is a white to off-white, very fine powder with an aqueous solubility of 2.22 mg/mL at 25°C.]] | 1) Saquinavir (Invirase) is known to be one of the first FDA approved protease inhibitor for HIV treatment. This usually occurs by HIV protease binding an active site tunnel tightly, which will prevent polyproteins from also binding. HIV’s chemical structure has the ability to mimic the tetrahedral intermediate of the hydrolytic reaction to interact strong with the catalytic Asp residues. Knowing that, Saquinavir is an uncleavable ligand by studying its similar conformational changes in binding saquinavir or a polypeptide. ((http://www.rxlist.com/invirase-drug.htm)))) [[Image:Saquin1.gif|thumb|Saquinavir mesylate is a white to off-white, very fine powder with an aqueous solubility of 2.22 mg/mL at 25°C.]] | ||
| Line 46: | Line 48: | ||
APPLICATIONS: | *APPLICATIONS: | ||
Design of a HIV-1 Protease inhibitor - Free-energy parameterization of enzyme-inhibitor binding. | Design of a HIV-1 Protease inhibitor - Free-energy parameterization of enzyme-inhibitor binding. | ||